![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/09\/20260922_Envisagenics_Boehringer_Ingelheim_Deal_and_Financing-768x432.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Envisagenics \/ Boehringer Ingelheim<\/p>\n Event Type<\/strong><\/p>\n Research Collaboration and Option Agreement<\/p>\n Modality<\/strong><\/p>\n ADCs, T Cell Engagers, Multispecific Antibodies<\/p>\n Asset<\/strong><\/p>\n SpliceCore-derived oncology targets<\/p>\n Target<\/strong><\/p>\n Tumor-specific splice junction antigens (undisclosed)<\/p>\n Disease Area<\/strong><\/p>\n Oncology<\/p>\n Envisagenics and Boehringer Ingelheim entered a multi year research and option agreement to discover and validate tumor specific targets derived from alternative RNA splicing. Boehringer may develop selected targets using antibody drug conjugates, T cell engagers and multispecific antibodies. Envisagenics can receive more than one billion dollars across upfront, research, options and milestones plus royalties; the upfront and number of targets are undisclosed.<\/p>\n The SpliceCore platform combines machine learning, large transcriptomic datasets and experimental validation and reportedly screens more than 14 million splicing events for disease specificity, prevalence and therapeutic suitability. Boehringer will choose modalities and lead development and commercialization for licensed targets.<\/p>\n No target sequence, tumor type, normal tissue expression atlas, validation package, option timing or per target economics were disclosed. The agreement therefore validates access to the discovery engine more than any individual medicine.<\/p>\n Interpretation one is that splice junction derived proteins can create tumor selective surface epitopes inaccessible to gene level analysis. That could expand the addressable antigen set for powerful immune and conjugate modalities. Against this, many RNA events are low abundance, heterogeneous or not translated into stable surface protein, and normal tissue datasets can miss rare but safety critical expression.<\/p>\n Interpretation two is that artificial intelligence improves prioritization at scale. The platform can rank millions of events, but model performance depends on sequencing quality, tumor purity, isoform annotation and prospective protein validation. For T cell engagers and ADCs, even small normal tissue expression can be consequential.<\/p>\n Upgrade evidence includes public targets, independent protein level confirmation, broad tumor prevalence, absent vital organ expression and in vivo therapeutic windows. Failure to reproduce splice products, low antigen density or on target off tumor toxicity would falsify the platform thesis.<\/p>\n Alternative RNA splicing generates different transcripts and proteins from the same gene. Cancer can create recurrent splice junctions or isoforms that are absent from most normal tissues. Envisagenics uses computational and experimental methods to identify such events. Boehringer can translate selected targets into biologics with distinct payload and immune activation risks.<\/p>\n This is a material discovery partnership with mixed interpretation. The economics and pharma commitment support the strategic relevance of RNA splicing derived targets, but no individual target is validated publicly. The decisive work is experimental: proving abundant tumor surface protein and a therapeutic window for modalities that can amplify low level normal tissue binding.<\/p>\n Signal Importance: 4 of 5. Signal Direction: mixed. Confidence in Facts: high for the collaboration terms disclosed. Confidence in Interpretation: moderate low because targets, data and upfront economics are confidential.<\/p>\n","protected":false},"excerpt":{"rendered":" Envisagenics and Boehringer Ingelheim entered a multi year research and option agreement to discover and validate tumor specific targets derived from alternative RNA splicing. Boehringer may develop selected targets using antibody drug conjugates, T…<\/p>\n","protected":false},"author":1,"featured_media":3383,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,2],"tags":[840,841,58],"class_list":["post-3361","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-deals-and-financing","tag-boehringer-ingelheim","tag-envisagenics","tag-oncology"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3361"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3361\/revisions"}],"predecessor-version":[{"id":3391,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3361\/revisions\/3391"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3383"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n